Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Non-Hodgkin's Lymphoma treatment details. Immunotherapy. Medical University of South Carolina, Charleston, SC, United States

Survival: 21.5 months
Toxicity Grade: 5
Treatments: Immunotherapy
Country: United States
City/State/Province: Charleston, SC
Hospital: Medical University of South Carolina
Journal: Link
Date: 3/2015

This phase 2 study involved 21 previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma patients. The median patient age was 63 years and 81% were male.

Patients received immunotherapy with ofatumumab (human anti-CD20 monoclonal antibody that directs immune system to attack cancer cells) and lenalidomide.

There was one treatment-related death due to infection. Grade 4 neutropenia and thrombocytopenia, grade 3 tumor flare reaction, and grade 2 infusion related reaction and fatigue were also reported.

The median overall survival was 21.5 months.

This study was supported by GlaxoSmithKline.

Correspondence: Dr. Luciano J. Costa; email:

E-mail to a Friend Email Physician More Information